Funding for this research was provided by:
Hilibrand Foundation
Hartwell Foundation
Article History
Accepted: 18 November 2020
First Online: 3 January 2021
Compliance with Ethical Standards
:
: James McPartland consults with BlackThorn Therapeutics, has received research funding from Janssen Research and Development, and receives royalties from Guilford Press, Lambert, and Springer. The other authors have no conflicts of interest to report.
: This study was deemed minimal risk and exempt from oversite by the Yale University Institutional Review Board (Project ID# 2000026330).